Delayed-interval delivery in a trichorionic triamniotic triplet pregnancy: Prolongation of pregnancy after premature delivery of two fetuses, a case report.

J Gynecol Obstet Hum ReprodJun 19, 2026 (epub)
Case ReportObstetrics & GynecologyPediatrics

Erika Lizette Rincón-Flores, María Fernanda Zalapa-Gómez, Lucy Salum-Rodríguez et al.

✦ AI-curated · Sources linked

Case in brief

A 31-year-old woman with a trichorionic triamniotic triplet pregnancy delivered two fetuses prematurely at 22 + 3 and 22 + 5 weeks. Despite sterile intraamniotic inflammation, management of the third fetus included broad-spectrum antibiotics and corticosteroids. At 27 + 5 weeks, a viable female infant was delivered, who faced complications but was eventually discharged after 77 days in the NICU.

Diagnostic / clinical pearl

Delayed-interval delivery in TCTA triplet pregnancies may improve outcomes when strict selection criteria are followed, emphasizing the need for individualized care.

Source

PubMed · PMID 42315087

Published in J Gynecol Obstet Hum Reprod. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Obstetrics & Gynecology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.